Tabár L, Chen H H, Fagerberg G, Duffy S W, Smith T C
Department of Mammography, Central Hospital, Cambridge, UK.
J Natl Cancer Inst Monogr. 1997(22):43-7. doi: 10.1093/jncimono/1997.22.43.
The effect of mammographic screening in reducing mortality from breast cancer is known to be smaller and more delayed in women aged 40-49 than in women over 50. In this study, we investigated how these phenomena relate to histology-specific breast cancer incidence and mortality. The data are from 2,468 women with breast cancer who participated in the Swedish Two-County Trial. The overall relative breast cancer mortality of invited to noninvited women aged 40-49 was 0.87, and the relative mortality from poorly differentiated (grade 3) ductal carcinoma was 0.95. These results were not statistically significant. The corresponding relative risks for invited women aged 50-74 were a statistically significant 0.65 and 0.61. We conclude that in this trial, with a two-year interscreening interval, the smaller and later effect of invitation to screening on breast cancer mortality in women 40-49 years old is due to the failure of screening to reduce mortality from grade 3 ductal carcinoma in this age group.
已知乳腺钼靶筛查在降低乳腺癌死亡率方面的效果,在40 - 49岁女性中比50岁以上女性更小且更延迟。在本研究中,我们调查了这些现象与组织学特异性乳腺癌发病率和死亡率之间的关系。数据来自参与瑞典双县试验的2468名乳腺癌女性。40 - 49岁受邀女性与未受邀女性的总体相对乳腺癌死亡率为0.87,低分化(3级)导管癌的相对死亡率为0.95。这些结果无统计学意义。50 - 74岁受邀女性相应的相对风险具有统计学意义,分别为0.65和0.61。我们得出结论,在本试验中,筛查间隔为两年,40 - 49岁女性受邀进行筛查对乳腺癌死亡率的效果较小且较晚出现,是由于筛查未能降低该年龄组3级导管癌的死亡率。